FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

被引：0

作者：

Moore, K. N. ^{[1
]}

Vergote, I. ^{[2
]}

Oaknin, A. ^{[3
]}

Colombo, N. ^{[4
]}

Banerjee, S. ^{[5
]}

Oza, A. M. ^{[6
]}

Pautier, P. ^{[7
]}

Kelly, C. M. ^{[8
]}

Malek, K. ^{[9
]}

Birrer, M. J. ^{[10
]}

机构：

[1] Univ Oklahoma, Stephenson Canc Ctr, Obstet & Gynecol, Oklahoma City, OK USA

[2] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium

[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[4] Ist Europeo Oncol, Dept Gynecol Oncol, Milan, Italy

[5] Royal Marsden, Gynaecol Unit, London, England

[6] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[7] Gustave Roussy Inst Cancerol, Med Oncol, Villejuif, France

[8] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Med Oncol, Dublin, Ireland

[9] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[10] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

991TiP

引用

页数：1

共 50 条

[1] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
Moore, Kathleen N.
Vergote, Ignace
Oaknin, Ana
Colombo, Nicoletta
Banerjee, Susana N.
Oza, Amit M.
Pautier, Patricia
Kelly, Catherine Margaret
Malek, Karim S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Moore, Kathleen N.
Martin, Lainie P.
O'Malley, David M.
Matulonis, Ursula A.
Konner, Jason A.
Perez, Raymond P.
Bauer, Todd M.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1112 - +
[3] FORWARD II: A phase Ib study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FRα)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer.
O'Malley, David M.
Martin, Lainie P.
Moore, Kathleen N.
Nepert, Dale L.
Ruiz-Soto, Rodrigo
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Backes, Floor
Wei, Lai
Copeland, Larry
Cohn, David
Fowler, Jeffrey
Bixel, Kristin
Cosgrove, Casey
Hays, John
Myers, Molly
Dodd, Kelly
O'Malley, David
GYNECOLOGIC ONCOLOGY, 2021, 162 : S68 - S69
[5] FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Moore, Kathleen N.
Vergote, Ignace
Oaknin, Ana
Colombo, Nicoletta
Banerjee, Susana
Oza, Amit
Pautier, Patricia
Malek, Karim
Birrer, Michael J.
FUTURE ONCOLOGY, 2018, 14 (17) : 1669 - 1678
[6] Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Moore, K. N.
Oza, A. M.
Colombo, N.
Oaknin, A.
Scambia, G.
Lorusso, D.
Konecny, G. E.
Banerjee, S.
Murphy, C. G.
Tanyi, J. L.
Hirte, H.
Konner, J. A.
Lim, P. C.
Prasad-Hayes, M.
Monk, B. J.
Pautier, P.
Wang, J.
Berkenblit, A.
Vergote, I
Birrer, M. J.
ANNALS OF ONCOLOGY, 2021, 32 (06) : 757 - 765
[7] Efficacy and safety of mirvetuximab soravtansine in Chinese patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from IMGN853-301 (Soraya China) study
Li, Li
Wu, Yong
Li, Qingshui
Yu, Aijun
Lin, An
Li, Guiling
Zhang, Huifeng
Wang, Jing
Li, Li
Yin, Rutie
Wei, Bing
Li, Jundong
Chen, Lihong
Zhao, Weidong
Wang, Wuliang
Zhang, Qinghua
Xu, June
Wu, Xiaohua
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A210 - A210
[8] A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
Trillsch, Fabian
Schochter, Fabienne
Park-Simon, Tjoung-Won
Reuss, Alexander
Fehm, Tanja N.
Wimberger, Pauline
Bronger, Holger
Schmalfeldt, Barbara
Sehouli, Jalid
Marme, Frederik
Heitz, Florian
Mahner, Sven
Fredrich, Michaela
Barth, Stefanie
Stec, James Joseph
Method, Michael W.
Harter, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts.
Moore, Kathleen N.
Matulonis, Ursula A.
O'Malley, David M.
Konner, Jason A.
Martin, Lainie P.
Perez, Raymond P.
Bauer, Todd Michael
Gilbert, Lucy
Seward, Shelly Marie
Oza, Amit M.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[10] PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
Backes, F.
Fowler, J.
Copeland, L.
Wei, L.
O'Malley, D.
Cohn, D.
Cosgrove, C.
Hays, J.
Bixel, K.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A13 - A14

← 1 2 3 4 5 →